Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization.
In a previous study, we observed a low frequency of HER-2/neu oncogene amplification in prostate cancer using fluorescent in situ hybridization (FISH). In our continued effort to identify prognostic biomarkers in prostate cancer, we analyzed 74 cases of prostate cancer to assess the presence of chromosomal trisomies in this cohort of patients. Previous results from this laboratory have implicated a role of chromosomal trisomies in various cancers. FISH using a chromosome 7 and a chromosome 8 centromere probe was utilized to study abnormal chromosome copy numbers together with data from a chromosome 17 control. The frequency of trisomy 7 was found to be 58.1% (43 of 74 informative cases), while the frequency of trisomy 8 was found to be 9.5% (7 of 74 informative cases). The frequency of cells showing chromosome 17 trisomy was 18.5% (15 of 81 cases successfully studied). While chromosome 8 trisomy did not seem to play as significant a role here as in other cancers that we studied, the results of chromosome 7 trisomy are consistent with those reported in the literature. Further exploration of selected trisomies as biomarkers in prostate cancer using a larger study sample size is warranted to establish their clinical utilities.
Mark
H F
HF
Department of Pathology, Rhode Island Hospital and Brown University School of Medicine, Providence 02903, Rhode Island.
Feldman
D
D
Das
S
S
Samy
M
M
Sun
C L
CL
Mark
S
S
D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17; D002897:Chromosomes, Human, Pair 7; D002898:Chromosomes, Human, Pair 8; D015331:Cohort Studies; D018734:Genes, erbB-2; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics*; D014314:Trisomy
D014408:Biomarkers, Tumor